Low-attenuation Coronary Plaque Burden May Become Next Big Cardiac Risk Assessment
There is a promising recent development in cardiovascular computed tomography angiography (CCTA) to analyze plaque to more accurately assess the risk of myocardial infarction (MI), determining which patients to put on aspirin and statins and to have the ability to monitor reversal of coronary inflammation using various drugs. This new plaque assessment technology, the fat attenuation index (FAI), was a big topic of discussion and one of the main take aways from the Society of Cardiovascular Computed Tomography (SCCT) 2020 virtual meting in July.
You are able to read the full article here.
Read more
April 2024
Newsweek Selects Caristo Diagnostics as One of World’s Best Digital Health Companies
Caristo Diagnostics, a leading cardiac disease diagnostics company, has been named by Newsweek as one of World’s Best Digital Health…
Read more
April 2024
Surrey Cardiovascular Clinic and Caristo Diagnostics Launch Employee Heart Wellness and Disease Prevention Program for UK Employers
Caristo’s AI technology predicts heart attack risk for employee wellness initiative from respected centre of excellence OXFORD, England and SURREY, England , April 23,…